Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018

Research output: Contribution to journalArticleScientificpeer-review


  • Kati Räisänen
  • Irma Koivula
  • Heikki Ilmavirta
  • Santeri Puranen

  • Teemu Kallonen
  • Outi Lyytikäinen
  • Jari Jalava

Research units

  • National Institute for Health and Welfare
  • University of Eastern Finland
  • University of Oslo


In December 2018, a ceftazidime-avibactam (CAZ-AVI)-resistant KPC-2-producing Klebsiella pneumoniae strain was isolated in Finland. CAZ-AVI resistance was observed 34 days after CAZ-AVI treatment in a trauma patient transferred from a hospital in Greece who had been colonised with blaKPC-2-producing K. pneumoniae ST39, and later developed a bloodstream infection. The CAZ-AVI-resistant strain contained a novel 15 amino acid insertion in the KPC-2 protein causing structural changes proximal to the KPC-2 active site.


Original languageEnglish
Pages (from-to)1-3
Issue number19
Publication statusPublished - 1 May 2019
MoE publication typeA1 Journal article-refereed

    Research areas

  • carbapenem, ceftazidime-avibactam, Klebsiella pneumoniae, resistance, whole-genome sequencing, KPC-2

Download statistics

No data available

ID: 35132942